Phosphoinositide-3-kinases are important targets for drug development because many proteins in the PI3 kinase signaling pathway are mutated, hyperactivated, or overexpressed in human cancers. Here, the authors coexpressed the human class Ia PI3 kinase p110α catalytic domain with an N-terminal His-tag and the p85α regulatory domain in Sf9 insect cells. The complex consisting of p110α and p85α was purified by nickel affinity chromatography. The authors established an adenosine triphosphate (ATP) depletion assay to measure the activity of p110α/p85α. The assay was optimized by testing different lipids as substrates, as well as various kinase and lipid concentrations. Furthermore, they analyzed autophosphorylation of p110α/p85α and determined the IC 50 for wortmannin, a known PI3 kinase inhibitor. The IC 50 for wortmannin was determined to be 7 nM. From a selection of substrates, phosphatidylinositol-4, 5-biphosphate turned out to be the best substrate at a concentration of 50 μM. p110α/p85α underwent autophosphorylation most prominently at the p85α subunit. However, in the presence of lipid substrate, the autophosphorylation was negligible. In parallel, a second assay format using the AlphaScreen technology was optimized to measure PI3 kinase activity. Both assay formats used should be suitable for high-throughput screening for the identification of
INTRODUCTION

P
HOSPHOINOSITIDE-3-KINASES (PI3 KINASES) are at the center of one of the major pathways of intracellular signal transduction. The signaling cascade involving these enzymes influences a wide variety of cellular functions. 1 Deregulation of the PI3K pathway is emerging as a common theme in diverse human diseases, and as a consequence, drugs that target PI3K will increasingly find therapeutic use. 2 PI3 kinases fall into 4 enzyme classes-Ia, Ib, II, and IIIwith different isoforms in each class. PI3 kinase α belongs to class Ia and consists of the p110α catalytic subunit and a p85 regulatory subunit. The p110α catalytic subunit of PI3 kinase α is frequently mutated in human cancers [3] [4] [5] and is generally accepted as a validated drug target. 6 Classically, PI3 kinases are assayed by using phosphatidylinositol-4,5-biphosphate (PIP2) liposomes as substrate together with radiolabeled adenosine triphosphate (ATP) in a kinase reaction followed by extraction of the lipids, thin-layer chromatography (TLC) or high-pressure liquid chromatography (HPLC), and subsequent scintillation counting. Yet, this is a nonhomogeneous assay not suitable for screening purposes. Alternatively, a homogeneous time-resolved fluorescence (HTRF) assay has been described. 7 Another high-throughput screening (HTS) method is based on fluorescence superquenching of a conjugated polymer upon metal ion-mediated association of phosphorylated and dye-labeled substrates. 8 Although both these latter assays are homogeneous and suitable for medium-to high-throughput screening, they require labeled substrate and additional costly reagents.
In this work, we describe the expression and purification of PI3 kinase α consisting of the p110α catalytic and p85α regulatory subunit and establish a homogeneous low-cost activity assay exploiting the fact that ATP is used up in the PI3 kinase reaction. In parallel, we optimized an assay format based on the AlphaScreen technology. Both assays gave comparable results. They are in principle suitable for all PI3 kinase isoforms and for HTS campaigns to find compounds interfering with the activity of PI3 kinase.
MATERIALS AND METHODS
Cloning and expression of PI3 kinase subunits
Human full-length PI3 kinase p110α subunit, cloned into pENTR221, was purchased from Invitrogen (Paisley, UK, clone IOH36362) and used for recombination with pDEST10 vector according to the manufacturer's protocol. A full-length clone for PI3 kinase p85α regulatory subunit was obtained from the DF/HCC DNA Resource Core (Harvard Institute of Proteomics, Cambridge, MA, accession number NM_181523). The coding region was amplified by polymerase chain reaction using the primers 5-CGGGATCCATGAGTGCTGAGGGGTACCAG (upstream primer) and 5-CGGATTCGCGCTTCATCGCCTCT-GCTGTG (downstream primer) and cloned into the vector pFASTBac1 using restriction sites BamHI and EcoRI and the bacterial strain DH5α. The sequence of the obtained bacterial clone was confirmed. It contained 2 point mutations, which did not change the encoded amino acid sequence (codon 217: GAA changed to GAG and codon 368: TAT exchanged to TAC). Recombination of the p110α/pDEST10 and p85α/pFASTBac1 with bacmid DNA was performed in the bacterial strain DH10Bac. Sf9 cells in a culture volume of 200 mL were transfected with the p110α/pDEST10 and p85α/pFASTBac1 recombinant bacmid DNA, and recombinant viruses were isolated. Expression of PI3 kinase α was achieved by coinfection of Sf9 cells at a density of 1 × 10 6 cells/mL using a multiplicity of infection (MOI) of 10 and 5 for p110α and p85α, respectively. Cells were harvested 72 h after infection.
Purification of PI3 kinase α α
Cell pellets from 500 mL coinfected Sf9 cells were suspended in 50 mL extraction buffer (20 mM NaH 2 PO 4 [pH 7.9], 500 mM NaCl, 50 mM imidazole, 1 tablet Complete Protease Inhibitor Cocktail, Roche [Basel, Switzerland], per 50-mL buffer) and sonicated. The soluble supernatant was loaded onto a 5-mL His-Trap HP column (GE Healthcare, Hilleroed, Denmark). The complex of p110α and p85α was eluted by a 25-mL gradient from 50 to 600 mM imidazole. Fractions containing both subunits were combined and dialyzed against 50 mM Tris-HCl (pH 7.9), 300 mM NaCl and kept at -80 °C.
ATP depletion PI3 kinase assay
PI3 kinase activity assay was performed in 96-well microplates (OptiPlate™-96, PerkinElmer LAS, Inc., Hvidovre, Denmark). The reaction had a total volume of 50 μL, containing 40 mM Tris-HCl (pH 7. .5], 10 mM NaCl, 10 mM DTT) by ultrasonication for 1 h. In addition, 2 water-soluble lipids were tested (PIP2-1,2-dipalmitoyl, sodium salt and PIP2-1,2-dioctanoyl, sodium salt, both from Cayman Chemical, Ann Arbor, MI). They were dissolved in assay buffer, and no solubilization step was needed. PI3 kinase (50-500 ng) was diluted in assay buffer containing 0.05% Brij 35 immediately prior to use. The kinase reaction was started by addition of an MgCl 2 /ATP mix and incubated at 22 °C for 10 to 120 min. After addition of 50 μL easylite-Kinase™ Luminescence Assay reagent (PerkinElmer LAS, Inc.), luminescence was read using a Victor™ Light luminometer (PerkinElmer LAS, Inc.).
Autophosphorylation of PI3 kinase α α
The kinase reaction as described above was performed with the following changes: 50 μL kinase reaction contained 500 ng PI3 kinase, 1.5 μg PIP2, and 1 μL γ-P 32 -ATP (3000 Ci/mmol, 10 mCi/mL, Hartmann Analytic, Braunschweig, Germany) at a final concentration of 10 μM ATP. The incubation was at 37 °C for 30 min. Samples were separated by 12.5% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and analyzed by Coomassie blue staining and autoradiography.
AlphaScreen PI3 kinase assay
A 10-μL PI3 kinase reaction was performed in white 384-well plates in a buffer consisting of 2.5 mM MgCl 2 , 5 mM HEPES (pH 7.4), 10 μM ATP, and 5 μM PIP2 substrate. Detection of the reaction product PIP3 was done using a commercially available kit (kit K-1300, Echelon, Salt Lake City, UT) in combination with the AlphaScreen GST detection kit (PerkinElmer LAS, Inc.) according to the manufacturer's recommendation. The detection buffer consisted of 10 mM Tris (pH 7.4), 150 mM NaCl, 1 mM DTT, and 0.1% Tween-20.
Signal was measured with an EnVision
® Multilabel plate reader equipped with an Alpha module (PerkinElmer LAS, Inc.).
RESULTS AND DISCUSSION
Expression and purification of PI3 kinase α α
The p110α subunit of PI3 kinase cloned into the pDEST10 vector allowed expression of p110α with an N-terminal His-tag. The p85α/pFASTBac1 construct led to expression of an untagged p85α subunit. Both subunits were clearly visible in crude extracts when expressed individually in Sf9 insect cells (not shown). However, the p110α subunit, when expressed alone, was insoluble in the extraction buffer used, whereas the p85α subunit was soluble. For coexpression, we used a coinfection at an MOI ratio for p110a to p85α of 2 and obtained an approximately 1:1 ratio of the 2 proteins in the crude extract (Fig. 1A) . When comparing the crude cellular extract with the soluble supernatant, no difference was seen, suggesting that both proteins were soluble.
The N-terminal His-tag of the p110α subunit facilitated purification by Ni-affinity chromatography applying a linear imidazole gradient. A single protein peak eluted at imidazole concentrations between 180 and 350 mM (Fig. 1B) . The peak contained both the p110α and p85α subunit (Fig. 1C) . Obviously, the 2 subunits had formed a complex to yield the PI3 kinase α enzyme. The purity of the obtained PI3 kinase α was approximately 85% (Fig. 1D) , and the yield was approximately 1.0 to 1.5 mg per 500 mL of the Sf9 cell culture.
Our yield was much lower than reported by Meier et al. 9 Meier et al. obtained 24 mg/L cell culture media, but they used culture volumes of 100 mL. They noticed that culture volumes larger than 100 mL resulted in dramatically lower p110 expression levels. On the other hand, Meier et al. obtained rather small amounts of p110α in the clarified cell lysate supernatant in comparison to p85α, resulting in 2 eluting peaks in the imidazole gradient during purification, one early eluting peak containing large amounts of p85α and a second small peak containing p110α/ p85α PI3 kinase α. In contrast, we obtained an approximately 1:1 ratio of p110α and p85α in the soluble supernatant and a single eluting peak containing PI3 kinase α. Hence, despite the considerable lower yield, when expressing the p110α/p85α PI3K in 200-mL volumes, as compared with smaller volumes, we tend to opt for the former approach because of the homogeneous production of the final product, which does not require further chromatographic separation steps.
Development of an ATP depletion PI3 kinase activity assay
PI3 kinase catalyzes the phosphorylation of PIP2 to PIP3 in the presence of Mg and ATP. Different methods have been described to measure activity. Other lipids such as PI, PIP, or mixtures of different lipids, lipids assembled in liposomes, and water-soluble PIP2 conjugates have been used as substrates. Here, we adopted a low-cost luminometric assay that measures the decrease of ATP to assay PI3 kinase activity. This ATP depletion assay is well established for protein kinases.
Because different lipids and mixtures of lipids have been described to be suitable as substrates, we have tested a selection of them ( Fig. 2A) . PI alone led to a signal decrease of 21%. PI in combination with the stabilizing lipid PS resulted in an 80% decrease (i.e., PS seems to be necessary for PI3 kinase activity toward PI as a substrate). Two other lipids, PC and PE, obviously had an inhibiting effect on PI3 kinase, seen by a signal decrease of 13% and 8%, respectively, when using PI as a substrate. PIP2, on the other hand, resulted in a 90% decrease of signal and thereby seems to be a better substrate than PI. Stabilizing lipids were not necessary to render it suitable as a substrate. We determined a concentration of 50 μM PIP2 as being optimal because 25 μM resulted in lower PI3K activity, whereas 100 μM gave the same result as 50 μM (results not shown). In addition to PIP2, which needed solubilization by extensive sonication prior to use, we tested 2 water-soluble PIP2 conjugates, PIP2-1,2-dipalmitoyl (sodium salt) and PIP2-1,2-dioctanoyl (sodium salt). The latter PIP2 conjugate led to a 10% decrease of signal (i.e., does not seem to be a good substrate), whereas PIP2-1,2-dipalmitoyl, at a concentration of 50 μM, gave rise to a decrease of 70%. To obtain a signal decrease of 90%, as measured for 50 μM of unconjugated PIP2, a concentration of 125 μM was needed (results not shown).
When we used PI3 kinase amounts between 50 and 200 ng in the assay and incubation times up to 2 h, we saw a decrease of ATP that correlated with the amount of PI3K and the incubation time (Fig. 2B) .
Autophosphorylation of PI3 kinase α α PI3 kinase has been described to be a dual-specificity enzyme displaying, beside lipid kinase activity, a protein-serine kinase activity detectable by autophosphorylation of the p85α subunit. 10 Because ATP depletion assays cannot distinguish between ATP consumption owing to autophosphorylation or substrate phosphorylation, we investigated this issue further. We observed a minor decrease of ATP, when incubating PI3 kinase α in the absence of substrate, probably due to autophosphorylation (Fig. 3A) . To demonstrate that autophosphorylation has occurred, we used radioactive ATP in the PI3 kinase reaction and separated the proteins by SDS-PAGE (Fig. 3B) Boldyreff et al. T o t a l A T P P I P I + P C P I + P S P I + P E P I + P C + P S + P E P I P 2 P I P 2 + P C + P S + P E P I P 2 followed by autoradiography (Fig. 3C) . Both PI3 kinase subunits became phosphorylated. The signal of the p85α regulatory subunit was much stronger than that of the p110α catalytic subunit. However, in the presence of PIP2 as a substrate, the autophosphorylation was almost negligible, supporting the notion that the decrease in ATP as measured in the ATP depletion assay (Fig. 3A) is virtually exclusively correlated with lipid substrate phosphorylation.
Optimization of an AlphaScreen PI3 kinase assay
An AlphaScreen assay to measure PI3 kinase α activity was optimized using a commercially available kit for the detection of PIP3. We performed a combined enzyme titration curve and time course (Fig. 4) . The data show that the signal is easily detected using 100 and 300 ng PI3 kinase α and an incubation time of 1 h. An ATP titration was performed using 200 ng PI3 kinase α, 5 μM substrate, and an incubation time of 1 h. A concentration of 10 μM ATP generates a decrease of approximately 50% in signal (data not shown). This concentration was considered as the apparent Km value.
Inhibition of PI3 kinase by wortmannin
Finally, we tested whether wortmannin, a known PI3 kinase inhibitor, was inhibiting recombinant PI3 kinase and determined the IC 50 value using the ATP depletion and the AlphaScreen assay using the assay conditions optimized in the previous experiments (Fig. 5) . The IC 50 value was determined to be 7 nM and 6.3 nM for the ATP depletion and the AlphaScreen assay, respectively, well in accordance with the value of 5 nM described by Okada et al.
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CONCLUSION
We have shown here that PI3 kinase α consisting of the catalytic p110α subunit and the regulatory p85α subunit can be expressed in the Sf9 insect cell system and purified to homogeneity in quantities of approximately 3 mg per liter cell culture. An ATP depletion assay and an AlphaScreen activity assay, suitable for screening of PI3K inhibitors, were optimized. Both assays gave equivalent IC 50 values for the inhibitor wortmannin (7 nM and 6.3 nM). The ATP depletion assay offers the advantage of being a lowcost assay because it does not require a labeled substrate, expensive additional reagents, or special instrumentation. It has been optimized in a 96-well plate format but could be run also in a 384-well format. The AlphaScreen assay needs additional reagents and equipment but is amenable to higher throughput than the ATP depletion assay. Both assays are homogeneous assays and might be further miniaturized to decrease enzyme consumption. 
